Affiliated Sites
  • Clinicians Network Payer Bioinformatics
Be The Match

Javascript disabled. This site requires JavaScript How to enable JavaScript.

You are using an outdated browser. Please upgrade your browser to improve your experience.

Close

NMDP

Be The Match
  • About Us
  • E-News Sign Up
  • My Cart
  • Transplant Indications and Outcomes
    • Disease-Specific Indications and Outcomes
      • AML - Adult
      • AML - Pediatric
      • ALL - Adult
      • ALL - Pediatric
      • MDS
      • CML
      • CLL
      • NHL
      • Hodgkin Lymphoma
      • Multiple Myeloma
      • Severe Aplastic Anemia & Marrow Failure
      • Sickle Cell Disease
      • Immune Deficiency Diseases
      • Inherited Metabolic Disorders
      • Thalassemia
      • Other Diseases
      • Multiple Sclerosis
      • Systemic Sclerosis
    • Additional Outcomes
      • Unrelated vs. Sibling Donor Outcomes
      • Older Patient Outcomes
      • Timing Impact on Outcomes
    • Eligibility
    • Referral Timing Guidelines
    • HLA Today
  • Transplant Therapy and Donor Matching
    • Cell Sources
    • HLA Typing and Matching
    • Donor or Cord Blood Search Process
      • Likelihood of Finding a Match
      • Preliminary Search Request
    • Jason Carter Clinical Trials Program
  • Post-Transplant Care
    • Early Complications
    • Vaccinations
    • Long-Term Care Guidelines
      • Pediatric Considerations
    • Chronic GVHD
      • Skin
      • Nails
      • Scalp and Body Hair
      • Eyes
      • Mouth
      • Lungs
      • Muscles, Fascia, Joints
      • Hematopoietic & Immune
      • GI Tract
      • Liver
      • Genitalia
      • Other
    • Post-Transplant Guidelines
  • Research and News
    • Browse Research
      • Pre-transplant blinatumomab reduces MRD, time to HCT for pediatric patients with B-ALL
      • Novel cytogenetic-based risk scores predict HCT outcomes for patients with CLL
      • Cryopreservation of allogenic HCT grafts does not adversely impact early post-HCT outcomes
      • Precision medicine initiative uses whole genome sequencing to identify novel prognostic signatures and the impact of genomic subgroups in MDS allogeneic HCT patients
    • Browse News
    • About Our Research
    • Transplant Enews
      • Advances in Transplant Enews
      • Resource Connection Enews
  • Resources and Education
    • HCT Presentation Slides
      • Hemaglobinopathies, Transplant Consultation Timing Guidelines
      • Myeloproliferative Neoplasms (MPN), Transplant Consultation Timing Guidelines
    • Patient Resources
    • Financial Resources
    • Materials Catalog
    • Obstetrician Resources
    • Education Catalog
      • Sickle Cell Disease: Exploring treatment options and psychosocial care
      • Continuing Education Discontinuation
      • Building Yourself From The Ground Up
      • Advances in HCT Over Time
      • HCT Graft Source Selection: Cord Blood
    • Technique Video
    • Umbilical Cord Blood Collection Training for Public Donation
  • Disease-Specific Indications and Outcomes
  • Additional Outcomes
  • Eligibility
  • Referral Timing Guidelines
  • HLA Today

Disease-Specific Indications and Outcomes

  • AML - Adult
  • AML - Pediatric
  • ALL - Adult
  • ALL - Pediatric
  • MDS
  • CML
  • CLL
  • NHL
  • Hodgkin Lymphoma
  • Multiple Myeloma
  • Severe Aplastic Anemia & Marrow Failure
  • Sickle Cell Disease
  • Immune Deficiency Diseases
  • Inherited Metabolic Disorders
  • Thalassemia
  • Other Diseases
  • Multiple Sclerosis
  • Systemic Sclerosis
Research Spotlight
  • Transplant Indications and Outcomes
  • Disease-Specific Indications and Outcomes
  • Multiple Sclerosis
  • Email
  • Print This Page

Multiple Sclerosis

Multiple sclerosis (MS) is a chronic, autoimmune, degenerative disease affecting nearly 1 million adults in the United States. [1] Most patients present with symptoms between 20 and 40 years of age but have varying rates of disability impairment. [2]

There is currently no cure for MS. However, research has shown that autologous hematopoietic cell transplantation (HCT) is an efficient and safe treatment for active relapsing forms of MS to help prevent relapse, lesion-activity, and worsening disability while limiting unexpected adverse events. [2] In addition, patients with aggressive forms of MS may particularly benefit from transplant accompanied by high-dose immunotherapy. [3,4] Together, these treatments suppress the autoimmune inflammatory response and promote immune recovery.

The American Society for Transplantation and Cellular Therapy (ASTCT) has recommended autologous transplant be considered for “standard of care, clinical evidence available” treatment of refractory-relapsing MS. [2]

Advances

Recent research shows promising treatment options and provides recommendations for clinical decision-making for patients with aggressive forms of MS, including:

  • Autologous HCT with high-dose chemotherapy for relapsing-remitting MS [4] 

  • Updated guidelines and recommendations for autoimmune diseases [5] 

  • Recommendations for autologous transplant by the National Multiple Sclerosis Society [6]

Outcomes

Data in this section was published by Muraro et al. using data from CIBMTR. [3]

Figure 1. Multiple Sclerosis Progression-Free Survival after Autologous HCT, 1995 to 2006

multiple sclerosis figure 1

Figure 2. Overall Survival after Autologous HCT, 1995 to 2006

multiple sclerosis figure 2

Referral Timing Guidelines

These guidelines highlight disease categories that include patients at risk for disease progression and who should be referred for a consultation for autologous or allogeneic transplantation.

Transplant Consultation Guidelines: Multiple Sclerosis

  • After MS relapse, with ≥ 2 relapse episodes in past 3 years, while on disease modifying therapy
  • Refer patient prior to progression of severe disability: patient must be able to walk 100 meters (with unilateral assistance: cane, crutch or brace)

Download as a slide (PPT)

View complete Referral Timing Guidelines

References

  1. National Multiple Sclerosis Society. Landmark Study Estimates Nearly 1 Million in the U.S. Have Multiple Sclerosis. February 15, 2019. Accessed June 9, 2022.  https://www.nationalmssociety.org/About-the-Society/News/Landmark-Study-Estimates-Nearly%C2%A01-Million-in-the-U
  2. Cohen JA, Baldassari LE, Atkins HL, et al. Autologous Hematopoietic Cell Transplantation for Treatment-Refractory Relapsing Multiple Sclerosis: Position Statement from the American Society for Blood and Marrow Transplantation. Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation. 2019;25(5):845-854. doi:10.1016/j.bbmt.2019.02.014.
  3. Muraro PA, Pasquini M, Atkins HL, et al. Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis. JAMA neurology. 2017;74(4):459-469. doi:10.1001/jamaneurol.2016.5867.
  4. Nash RA, Hutton GJ, Racke MK, et al. High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS. Neurology. 2017;88(9):842-852. doi:10.1212/WNL.0000000000003660.
  5. Sharrack B, Saccardi R, Alexander T, et al. Autologous hematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE). Bone marrow transplantation. 2020;55(2):283-306. doi:10.1038/s41409-019-0684-0.
  6. Miller AE, Chitnis T, Cohen BA, Costello K, Sicotte NL, Stacom R. Autologous Hematopoietic Stem Cell Transplant in Multiple Sclerosis: Recommendations of the National Multiple Sclerosis Society. JAMA neurology. 2021;78(2):241-246. doi:10.1001/jamaneurol.2020.4025.
  • Email
  • Print This Page

Slides may be downloaded and used without permission for one-time presentation or personal use.  For publication, use in print or web, or repeated presentations, please submit a Copyright Request Form.

Transplant Indications and Outcomes

  • Disease-Specific Indications and Outcomes
  • Additional Outcomes
  • Eligibility
  • Referral Timing Guidelines
  • HLA Today

Transplant Therapy and Donor Matching

  • Cell Sources
  • HLA Typing and Matching
  • Donor or Cord Blood Search Process
  • Jason Carter Clinical Trials Program

Resources and Education

  • HCT Presentation Slides
  • Patient Resources
  • Financial Resources
  • Materials Catalog
  • Obstetrician Resources
  • Education Catalog
  • Technique Video
  • Umbilical Cord Blood Collection Training for Public Donation

Contact Us

About Us

Our Websites

bethematch.org
BeTheMatch.org Information and support for patients, donors and supporters of our mission.
BeTheMatchBioTherapies.com
BeTheMatchBioTherapies.com Proven solutions for organizations developing and delivering new cellular therapies
CIBMTR.org
CIBMTR.org Transplant research, clinical studies, publications and outcomes data for researchers and clinicians.
National Marrow Donor Program —
Entrusted and under contract to operate the C.W. Bill Young Cell Transplantation Program, including Be The Match Registry®.
Copyright © 1996-2022 National Marrow Donor Program. All Rights Reserved. Terms of Use | Privacy Policy | Trademark & Copyright